BridgeBio Oncology Therapeutics Statistics
Want to see BBOT full AI Analyst Report?
BridgeBio Oncology Therapeutics (BBOT) Stock Statistics & Valuation Metrics
Total Valuation
BridgeBio Oncology Therapeutics has a market cap or net worth of $158.90M. The enterprise value is $137.27M.
- Market Cap
- $158.90M
- Enterprise Value
- $137.27M
Share Statistics
BridgeBio Oncology Therapeutics has 80,251,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 80,251,270
- Owned by Insiders
- 22.45%
- Owned by Institutions
- 69.98%
Financial Efficiency
BridgeBio Oncology Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.23%.
- Return on Equity (ROE)
- -0.33
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -35.23%
- Return on Capital Employed (ROCE)
- -0.35
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.46M
- Employee Count
- 92
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BridgeBio Oncology Therapeutics is -0.00. BridgeBio Oncology Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.54
- Price to FCF
- -1.05
- Price to Operating Cash Flow
- -1.05
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, BridgeBio Oncology Therapeutics had revenue of 0 and earned -134.04M in profits. Earnings per share was -4.30.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -145.82M
- Pretax Income
- -134.04M
- Net Income
- -134.04M
- EBITDA
- -145.21M
- Earnings Per Share (EPS)
- -4.30
Cash Flow
In the last 12 months, operating cash flow was -150.88M and capital expenditures -157,000, giving a free cash flow of -151.03M billion.
- Operating Cash Flow
- -150.88M
- Free Cash Flow
- -151.03M
- Free Cash Flow per Share
- -1.88
Dividends & Yields
BridgeBio Oncology Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -96.27%
- Earnings Yield
- -109.42%
Stock Price Statistics
- Beta
- 0.69
- 52-Week Price Change
- -85.87%
- 50-Day Moving Average
- 3.65
- 200-Day Moving Average
- 7.59
- Relative Strength Index (RSI)
- 30.24
- Average Volume (3m)
- 623.11K
Important Dates
BridgeBio Oncology Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
BridgeBio Oncology Therapeutics as a current ratio of 12.14, with Debt / Equity ratio of 0.67%
- Current Ratio
- 12.14
- Quick Ratio
- 12.14
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 2.55
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BridgeBio Oncology Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BridgeBio Oncology Therapeutics EV to EBITDA ratio is -0.46, with an EV/FCF ratio of -0.55.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.46
- EV to Free Cash Flow
- -0.55
- EV to Operating Cash Flow
- -0.55
Balance Sheet
BridgeBio Oncology Therapeutics has $193.87M in cash and marketable securities with $2.38M in debt, giving a net cash position of $191.49M billion.
- Cash & Marketable Securities
- $193.87M
- Total Debt
- $2.38M
- Net Cash
- $191.49M
- Net Cash Per Share
- $2.39
- Tangible Book Value Per Share
- $3.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for BridgeBio Oncology Therapeutics is $18.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $18.88
- Price Target Upside
- 872.94% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -132725.78%
Scores
- Smart Score
- 6
- AI Score
- 43

